BACKGROUND: The prevalence of cardiometabolic disease in Africa now rivals that of Western nations. Therefore, screening programs that lead to effective prevention of cardiometabolic disease in Africans is imperative. Most screening tests for cardiometabolic disease use triglyceride (TG) levels as a criterion. However, the failure rate of TG-based screening tests in African Americans is high. In Africans, the efficacy of TG-based screening tests is unknown. Our goal was to determine the association between hypertriglyceridemia (TG ≥150 mg/dL) and cardiometabolic disease in African and African-American men. RESEARCH DESIGN AND METHODS: This was a cross-sectional study of 155 men (80 African immigrants, 75 African Americans) [age, 35±9 years, mean±standard deviation (SD), body mass index (BMI) 28.5±5.2 kg/m(2)] who self-identified as healthy. Lipid profiles were performed. Glucose tolerance and insulin resistance was determined by oral glucose tolerance tests (OGTT) and the insulin sensitivity index (S(I)), respectively. Cardiometabolic disease was defined by four possible subtypes--prediabetes, diabetes, insulin resistance, or metabolic triad [hyperinsulinemia, hyperapolipoprotein B, small low-density lipoprotein (LDL) particles]. RESULTS: TG levels were higher in men with cardiometabolic disease than without (88±43 versus 61±26 mg/dL, P<0.01). However, <10% of men with cardiometabolic disease had TG ≥150 mg/dL. Even within each cardiometabolic disease subtype, the prevalence of TG ≥150 mg/dL was <10%. Furthermore, TG levels in the 5% of men identified by OGTT as diabetic were ≤100 mg/dL (mean 71±24, range 45-100 mg/dL). CONCLUSIONS: Hypertriglyceridemia is a poor marker of cardiometabolic disease in men of African descent. Therefore TG-based screening tests fail to identify both African immigrants and African-American men with cardiometabolic disease. As a consequence, the opportunity for early intervention and prevention is lost.
BACKGROUND: The prevalence of cardiometabolic disease in Africa now rivals that of Western nations. Therefore, screening programs that lead to effective prevention of cardiometabolic disease in Africans is imperative. Most screening tests for cardiometabolic disease use triglyceride (TG) levels as a criterion. However, the failure rate of TG-based screening tests in African Americans is high. In Africans, the efficacy of TG-based screening tests is unknown. Our goal was to determine the association between hypertriglyceridemia (TG ≥150 mg/dL) and cardiometabolic disease in African and African-American men. RESEARCH DESIGN AND METHODS: This was a cross-sectional study of 155 men (80 African immigrants, 75 African Americans) [age, 35±9 years, mean±standard deviation (SD), body mass index (BMI) 28.5±5.2 kg/m(2)] who self-identified as healthy. Lipid profiles were performed. Glucose tolerance and insulin resistance was determined by oral glucose tolerance tests (OGTT) and the insulin sensitivity index (S(I)), respectively. Cardiometabolic disease was defined by four possible subtypes--prediabetes, diabetes, insulin resistance, or metabolic triad [hyperinsulinemia, hyperapolipoprotein B, small low-density lipoprotein (LDL) particles]. RESULTS:TG levels were higher in men with cardiometabolic disease than without (88±43 versus 61±26 mg/dL, P<0.01). However, <10% of men with cardiometabolic disease had TG ≥150 mg/dL. Even within each cardiometabolic disease subtype, the prevalence of TG ≥150 mg/dL was <10%. Furthermore, TG levels in the 5% of men identified by OGTT as diabetic were ≤100 mg/dL (mean 71±24, range 45-100 mg/dL). CONCLUSIONS:Hypertriglyceridemia is a poor marker of cardiometabolic disease in men of African descent. Therefore TG-based screening tests fail to identify both African immigrants and African-American men with cardiometabolic disease. As a consequence, the opportunity for early intervention and prevention is lost.
Authors: J P Després; C Couillard; J Gagnon; J Bergeron; A S Leon; D C Rao; J S Skinner; J H Wilmore; C Bouchard Journal: Arterioscler Thromb Vasc Biol Date: 2000-08 Impact factor: 8.311
Authors: Sherita Hill Golden; Arleen Brown; Jane A Cauley; Marshall H Chin; Tiffany L Gary-Webb; Catherine Kim; Julie Ann Sosa; Anne E Sumner; Blair Anton Journal: J Clin Endocrinol Metab Date: 2012-06-22 Impact factor: 5.958
Authors: Anne E Sumner; Sabyasachi Sen; Madia Ricks; Barbara A Frempong; Nancy G Sebring; Harvey Kushner Journal: Obesity (Silver Spring) Date: 2008-02-21 Impact factor: 5.002
Authors: Erik J Rodriquez; Edward N Kim; Anne E Sumner; Anna M Nápoles; Eliseo J Pérez-Stable Journal: J Urban Health Date: 2019-03 Impact factor: 3.671
Authors: Jean N Utumatwishima; Rafeal L Baker; Brianna A Bingham; Stephanie T Chung; David Berrigan; Anne E Sumner Journal: J Racial Ethn Health Disparities Date: 2017-04-25
Authors: Amber B Courville; Shanna B Yang; Sarah Andrus; Nosheen Hayat; Anneliese Kuemmerle; Elizabeth Leahy; Sara Briker; Kirsten Zambell; Stephanie Chung; Anne E Sumner Journal: Nutrition Date: 2020-01-18 Impact factor: 4.008
Authors: Stephanie T Chung; Celeste K L Cravalho; Abby G Meyers; Amber B Courville; Shanna Yang; Nirupa Rachel Matthan; Lilian Mabundo; Maureen Sampson; Ronald Ouwerkerk; Ahmed M Gharib; Alice H Lichtenstein; Alan T Remaley; Anne E Sumner Journal: Circ Res Date: 2019-10-18 Impact factor: 17.367
Authors: Liyun Wang; Frank M Sacks; Jeremy D Furtado; Madia Ricks; Amber B Courville; Anne E Sumner Journal: Nutr Metab (Lond) Date: 2014-12-17 Impact factor: 4.169
Authors: Anne E Sumner; Caroline K Thoreson; Michelle Y O'Connor; Madia Ricks; Stephanie T Chung; Marshall K Tulloch-Reid; Jay N Lozier; David B Sacks Journal: Diabetes Care Date: 2014-10-22 Impact factor: 19.112
Authors: Anne E Sumner; Jeremy D Furtado; Amber B Courville; Madia Ricks; Novie Younger-Coleman; Marshall K Tulloch-Reid; Frank M Sacks Journal: Nutr Metab (Lond) Date: 2013-12-23 Impact factor: 4.169